300 related articles for article (PubMed ID: 34353856)
1. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
2. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
3. miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway.
Takagawa Y; Gen Y; Muramatsu T; Tanimoto K; Inoue J; Harada H; Inazawa J
Mol Ther; 2020 Jun; 28(6):1494-1505. PubMed ID: 32320642
[TBL] [Abstract][Full Text] [Related]
4. NF-κB maintains the stemness of colon cancer cells by downregulating miR-195-5p/497-5p and upregulating MCM2.
Wang L; Guo J; Zhou J; Wang D; Kang X; Zhou L
J Exp Clin Cancer Res; 2020 Oct; 39(1):225. PubMed ID: 33109220
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA MALAT1 Promotes Laryngocarcinoma Development by Targeting miR-708-5p/BRD4 Axis to Regulate YAP1-Mediated Epithelial-Mesenchymal Transition.
Wu X; Tan Y; Tang X
Biomed Res Int; 2022; 2022():8093949. PubMed ID: 35601153
[TBL] [Abstract][Full Text] [Related]
6. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression.
Zheng J; Zhang Y; Cai S; Dong L; Hu X; Chen MB; Zhu YH
Cancer Lett; 2020 Apr; 476():129-139. PubMed ID: 32081805
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
Wang R; You J
J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
11. Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression.
Cao MX; Zhang WL; Yu XH; Wu JS; Qiao XW; Huang MC; Wang K; Wu JB; Tang YJ; Jiang J; Liang XH; Tang YL
J Exp Clin Cancer Res; 2020 Jun; 39(1):102. PubMed ID: 32493454
[TBL] [Abstract][Full Text] [Related]
12. Supercharging BRD4 with NUT in carcinoma.
Eagen KP; French CA
Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
14. MiR-361-5p exerts tumor-suppressing functions in gastric carcinoma by targeting syndecan-binding protein.
Qian B; Zhang D; Tao R; Yu G; Jia B; Ye K; Ma L; Wan S; Wu W
Anticancer Drugs; 2020 Feb; 31(2):131-140. PubMed ID: 31850945
[TBL] [Abstract][Full Text] [Related]
15. ΔNp63α is a super enhancer-enriched master factor controlling the basal-to-luminal differentiation transcriptional program and gene regulatory networks in nasopharyngeal carcinoma.
Cai J; Chen S; Yi M; Tan Y; Peng Q; Ban Y; Yang J; Li X; Zeng Z; Xiong W; McCarthy JB; Li G; Li X; Xiang B
Carcinogenesis; 2020 Sep; 41(9):1282-1293. PubMed ID: 31826234
[TBL] [Abstract][Full Text] [Related]
16. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
18. Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.
Ai C; Ma G; Deng Y; Zheng Q; Gen Y; Li W; Li Y; Zu L; Zhou Q
Thorac Cancer; 2020 Mar; 11(3):640-650. PubMed ID: 32022430
[TBL] [Abstract][Full Text] [Related]
19. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.
Yang C; Wu K; Wang S; Wei G
J Cell Biochem; 2018 Jul; 119(7):5646-5656. PubMed ID: 29384226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
